Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites (MM09-SIT-023)



Status and phase

Phase 3


Asthma, Allergic
Rhinitis, Allergic


Biological: 10,000 MM09
Biological: 30,000 MM09
Biological: Placebo subcutaneous

Study type


Funder types



2018-004262-34 (EudraCT Number)

Details and patient eligibility


A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with mild to moderate asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

Full description

Double blind, multicenter, parallel placebo controlled study. It includes 150 subjects sensitised to mites, from 14 to 65 years of age. Medication treatment of 1 year. The main outcome: CSMS


150 estimated patients




14 to 65 years old


No Healthy Volunteers

Inclusion criteria

  • Written informed consent.

  • Age between 14 and 65, both genders.

  • Positive suggestive clinical history of controlled intermittent or persistent asthma with intermittent or persistent moderate to severe rhinitis /rhinoconjunctivitis, due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent form

  • Subjects with a positive skin prick-test wheal size >5 mm higher diameter due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. The positive and negative control of the test should give consistent results

  • Specific immunoglobulin E against house dust mites >3,5 KU/mL (InmunoCAP® o Immulite), for the complete extract of Dermatophagoides pteronyssinus and / or for Dermatophagoides farinae or for some of the molecular components of these allergenic sources

  • Subjects should preferably be monosensitized to the study allergens. In case of subjects sensitized to other aeroallergens, only those with the following characteristics may be included in the study:

    • Subjects with positive skin test to Blomia tropicalis and Lepidoglyphus destructor, whose specific IgE values do not exceed or equal the values for the study allergens. The maximum specific IgE value for these allergens is 3.5 KU/L.
    • Subjects with positive skin tests to epithelia, as long as they present occasional exposure and symptomatology.
    • Subjects with positive skin tests to pollens, whose specific IgE values do not exceed or equal the values of the allergens in the study and who do not present exacerbations during the pollen season. The maximum value of specific IgE for these allergens is 17.5 KU/L.
  • Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial, before the first administration of the IMP.

  • Women of childbearing age participating in the trial must agree to use an appropriate method of contraception, meaning any act, device, or medication to prevent conception or viable pregnancy, during the trial if they are sexually active.

  • Subjects with a diagnosis of asthma according to the GEMA 5.0 guideline.

  • Subjects capable of complying with the dosing regimen.

  • Subjects who own an smartphone for symptom registration and medication

Exclusion criteria

  • Subjects with positive prick test to fungus, whose specific IgE is <0,35 KU/L
  • Subjects with positive prick test to epiteliums, whose specific IgE is <0,35 KU/L
  • Subjects who have received prior immunotherapy in the preceding 5 years for any of the epiteliums, fungus and dust mites.
  • Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.
  • Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 <70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated.
  • Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test.
  • Subjects under treatment with β-blockers.
  • Clinically unstable subjects at the time of inclusion in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.).
  • Subjects with active chronic urticaria, severe dermography, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin tests are performed, or a history of hereditary angioedema.
  • Subjects that have some pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc.).
  • Subjects with some other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple operations, kidney disease,).
  • Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.
  • Subject whose status prevents him from offering cooperation and or who has severe psychiatric disorders.
  • Subjects with a known allergy to other components of the investigational medicinal product other than the allergen.
  • Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis.
  • Direct investigator's relatives.
  • Pregnant women or breastfeeding women.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

150 participants in 3 patient groups, including a placebo group

Experimental:10,000 MM09
Experimental group
10,000 TU/mL of subcutaneous immunotherapy
Biological: 10,000 MM09
Experimental: 30,000 MM09
Experimental group
30,000 TU/mL of subcutaneous immunotherapy
Biological: 30,000 MM09
Placebo subcutaneous
Placebo Comparator group
The same solution and presentation as the active treatment, but without any active ingredients.
Biological: Placebo subcutaneous

Trial contacts and locations



Central trial contact

Francisco Moreno, MD; Miguel Casanovas, MD PhD

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems